Topoisomerase (topo) II␣ and II␤ maintain genome stability and are targets for anti-tumor drugs. In this study, we demonstrate that the decatenation checkpoint is regulated, not only by topo II␣, as previously reported, but also by topo II␤. The decatenation checkpoint is most efficient when both isoforms are present. Regulation of this checkpoint and sensitivity to topo II-targeted drugs is influenced by the C-terminal domain (CTD) of the topo II isoforms and by a conserved non-catalytic tyrosine, Y640 in topo II␣ and Y656 in topo II␤. Deletion of most of the CTD of topo II␣, while preserving the nuclear localization signal (NLS), enhances the decatenation checkpoint and sensitivity to topo II-targeted drugs. In contrast, deletion of most of the CTD of topo II␤, while preserving the NLS, and mutation of Y640 in topo II␣ and Y656 in topo II␤ inhibits these activities. Structural studies suggest that the differential impact of the CTD on topo II␣ and topo II␤ function may be due to differences in CTD charge distribution and differential alignment of the CTD with reference to transport DNA. Together these results suggest that topo II␣ and topo II␤ cooperate to maintain genome stability, which may be distinctly modulated by their CTDs.
INTRODUCTION
Topoisomerase (topo) II alters DNA topology by resolving supercoils and catenations in chromosomal DNA (1) (2) (3) . This enzyme plays a vital role in DNA metabolic processes, including chromosome condensation and segregation and transcription. In vertebrates two isoforms of topo II, topo II␣ and topo II␤, are present. These isoforms are structurally similar in the N-terminal ATP binding domain and the DNA binding catalytic domain (1) (2) (3) . However, the C-terminal domains of topo II␣ and topo II␤ exhibit only 22% identity. Although topo II␣ and topo II␤ display similar catalytic activities they exhibit distinct functional activities, which in part may be due to the structural diversity of the C-terminal domain (CTD). Extensive studies of the topo II␣ isoform have shown that it is expressed in proliferating cells during the S and G2M phases of the cell cycle and is primarily involved in regulating cell proliferation (1) (2) (3) (4) (5) . However, the topo II␤ isoform, which is constitutively expressed (4, 5) , is mainly associated with cell differentiation (6) (7) (8) (9) and transcription (10, 11) . Studies in topo II␤ knockout mice support a role for this isoform in neuronal development (12) .
The decatenation activity of topo II is essential for separating the entangled sister chromatids that form during DNA replication. The efficient removal of the catenae is required for proper chromosome condensation in prophase and chromosome segregation in anaphase. Consequently, perturbation of topo II activity prevents decatenation and disentanglement of the chromosomes and leads to activa-5996 Nucleic Acids Research, 2017, Vol. 45, No. 10 tion of the decatenation checkpoint, which delays progression of G2 cells into mitosis (13) (14) (15) . Activation of this checkpoint, which is distinct from the DNA damage checkpoint (16) , is essential for maintaining cellular integrity and genome stability. Thus a defective checkpoint could lead to genome instability, aneuploidy and development of cancer. Although the mechanism by which cells activate the decatenation checkpoint is not fully understood, it has been suggested that a chromatin structural feature probably involving the presence of a topo II dimer in association with catenated DNA serves as a sensor for activating this checkpoint (17) . Studies evaluating the decatenation checkpoint using topo II catalytic inhibitors, such as the bisdioxopiperazine, ICRF-193 to perturb topo II activity have suggested that topo II␣ is the main isoform involved in regulating this checkpoint (18) (19) (20) . Given the almost identical catalytic activities of topo II␣ and topo II␤ and the essential nature of topo II activity in maintaining cellular integrity, these isoforms could exhibit overlapping functional activities. The topo II isoforms may be uniquely regulated by interactions with protein complexes, post-translational modifications (PTMs) or by localizations to specific regions within the nucleus (21) . For such regulation the divergent CTD likely plays an important role. In this study, we examined the role of both isoforms in regulating the decatenation checkpoint and evaluated the influence of deleting the CTD as well as mutating a conserved non-catalytic tyrosine that was previously shown to alter the in vitro catalytic activity of topo II␤ (22) . Further, the sensitivity of wild type (WT) and mutant forms of topo II␣ and topo II␤ to topo II-targeted drugs was also studied
MATERIALS AND METHODS

Reagents
Polyclonal antibodies for topo II␣ and topo II␤ have been described previously (22, 23) . The antibody to myc-tag protein (clone A46) was obtained from EMD Millipore (Billerica, MA). Anti-␤-actin-peroxidase antibody (clone AC-15) was purchased from Sigma-Aldrich (St. Louis, MO, USA). Geneticin and puromycin were obtained from Life Technologies (Carlsbad, CA, USA). Tetracycline (Tet) was obtained from Sigma-Aldrich (St. Louis, MO, USA). The topo II catalytic inhibitor ICRF-193 was obtained from MP Biomedicals (Santa Ana, CA, USA). The topo II-targeting drugs etoposide (VP-16) and amsacrine (m-AMSA) were obtained from Sigma-Aldrich (St. Louis, MO) and the NCI, NIH, respectively. Stock solutions of these drugs were prepared in dimethyl sulfoxide (Sigma-Aldrich, St. Louis, MO) and stored at -20
• C. Karyomax ® colcemid solution was obtained from Life Technologies (Carlsbad, CA, USA). Muse H2A.X activation dual detection kit was obtained from EMD Millipore (Billerica, MA, USA). Vectashield mounting medium for fluorescence with DAPI was purchased from Vector Laboratories Inc. (Burlingame, CA, USA). Kinetoplast DNA (kDNA) was obtained from Topogen (Columbus, OH, USA).
Construction of human WT and mutant topo II␣ and topo II␤ cDNA plasmids
WT topo II␣ and topo II␤ (topo II␤ sequence based on isoform 1 comprising of 1621 amino acids--NCBI accession NP 001059) cDNAs contained a c-Myc and 6xHis linker at the 3 end. C-terminal deleted (C-del) topo II␣ corresponding to deletion of K1201-Q1453 and F1498-F1531 and Cdel topo II␤ corresponding to deletion of K1219-S1521 and Q1574-N1621, were constructed by site-directed mutagenesis of the WT cDNA using the Quick-change site-directed mutagenesis kit (Agilent Technologies, Inc., Santa Clara, CA, USA). In both C-del constructs the nuclear localization signals (K1454-D1497 for topo II␣ and E1522-R1573 for topo II␤) were preserved (24) . The primer set for topo II␣ K1201-Q1453 deletion was 5 -AAG CCT GAT CCT GCC AAA ACC AAG AAT CG-3 and 5 -GG CCT TCC CCC CTT TCC CAG -3 , whereas the primer set for topo II␣ -D1498-F1531 deletion was 5 -GAA CAA AAG TTG ATC TCT GAA GAA GAC TTG AAC-3 and 5 -GTC ATC ACT CTC CCC CTT GG-3 . The primer set for topo II␤ K1219-S1521 deletion was 5 -AGG TTT GCC AAC TTT ACC TTT AAT TG-3 and 5 -GAA TTT GGC ATT CCA AAG AAG ACT ACA AC-3 , whereas the primer set for topo II␤ Q1574-N1621 deletion was 5 -ATC AAA AGA TGT CTT CTT CGG TTT CTT GC-3 and 5 -GAA CAA AAG TTG ATC TCT GAA GAA GAC TTG AAC-3 . The Y640F mutant topo II␣ and Y656F mutant topo II␤ cDNA were also constructed by site-directed mutagenesis. The primer set used for generating the Y640F mutant topo II␣ was, 5 -CAT CGT ATC CAG TTC AAA TTT  TCT GGT CCT GAA GAT GAT GCT GC-3 and 5 -GC  AGC ATC ATC TTC AGG ACC AGA AAA TTT GAA  CTG GAT ACG ATG-3 . The primer set used for generating the Y656F mutant topo II␤ was 5 -CGC ATC TTG  TTT AGA TTT GCT GGT CCT GAA GAT GAT GC-3  and 5 -GC ATC ATC TTC AGG ACC AGC AAA TCT  AAA CAA GAT GCG-3 . These cDNAs were cloned in the pHT212 plasmid and transformed in the Saccharomyces cerevisiae yeast strain, BJ201, for preparing recombinant protein for in vitro decatenation assay as described earlier (22, 23) . The cDNAs were also cloned in the neo-containing IRES-enhanced green fluorescent protein expression pEIE vector described earlier (8) for expressing the recombinant proteins in the genetically engineered fibrosarcoma cell line, HTETOP (25) and in the m-AMSA-resistant HL-60 cell line (HL-60/AMSA-R), which does not express the topo II␤ protein (8, 26) .
Cell lines stably expressing WT or mutant topo II isoform or topo II isoform-targeted shRNA
The HTETOP cell line described earlier (25) is a genetically engineered HT1080 cell line in which both alleles of topo II␣ are disrupted and the cells are stably transfected with an exogenous topo II␣ cDNA (referred to as parental topo II␣) controlled by the Tet transactivator (tTA). These cells were cultured in advanced DMEM (Life Technologies, Carlsbad, CA) supplemented with 2 mM L-glutamine (Life Technologies, Carlsbad, CA, USA) and 10% fetal bovine serum (Atlanta Biologicals Inc., Lawrenceville, GA, USA) in a humidified atmosphere of 5% CO 2 and 95% air. Although these cells are not viable in the presence of Tet due to silencing of >99.5% topo II␣ expression and low levels of endogenous topo II␤ expression, Tet-resistant clones can be selected after stable transfection with expression plasmids of either topo II␣ or topo II␤ (27) . Accordingly, HETEOP cells were transfected with the WT or mutant topo II␣ or topo II␤ expression plasmids described above and the transfected cells were selected in the presence of 1 g/ml Tet in advanced DMEM supplemented with 2 mM L-glutamine and 10% fetal bovine serum. Once selected the stably transfected cells were grown in the presence or absence of Tet to express either the transfected topo II isoform alone or the transfected topo II isoform plus the parental Tet-regulated topo II␣ protein, respectively. Prior to initiation of any experiment, cells were cultured in the experimental condition (+ Tet or -Tet) for at least 2 weeks. Supplementary Table S1 and Supplementary Figure S1 show the expression of the specific topo II isoforms in the presence or absence of Tet for each cell line.
Construction of HL-60 cells (ATCC, Manassas, VA, USA) stably transfected with topo II␣ or topo II␤ sh-RNA (HL-60/si-topo II␣ or HL-60/si-topo II␤, respectively) as well as the HL-60/AMSA-R stably transfected with WT topo II␤ cDNA (HL-60/AMSA-R/topo II␤) was previously described (8) . Cultures of these HL-60 cells were maintained in RPMI-1640 supplemented with 10% fetal bovine serum and 2 mM L-glutamine at 37
• C in a humidified atmosphere of 5% CO 2 and 95% air. Compared to control HL-60/siGFP cells, the degree of stable down regulation of topo II␣ and topo II␤ in the HL-60/si-topo II␣ and HL-60/si-topo II␤ cell lines was 72 ± 7.2% and 96 ± 4.1%, respectively (Supplementary Figure S2) , even when these cell lines were maintained in the absence of the selection marker, puromycin. Mouse embryonic fibroblasts (MEF) MEF ␤+/+ and MEF ␤-/− , immortalized with simian virus 40 (SV40) large T antigen transformation were a generous gift from Dr Gloria Li, Memorial Sloan Kettering Cancer Center, New York, NY (12, 28) . The MEF ␤+/+ and MEF ␤-/-cells were cultured in RPMI-1640 supplemented with 10% fetal bovine serum and 2 mM L-glutamine at 37
• C in a humidified atmosphere of 5% CO 2 and 95% air.
Preparation of cell lysates and western blot analysis
Total cell lysates were prepared in radioimmunoprecipitation assay (RIPA) buffer as described earlier (23) . Equivalent aliquots of cell lysates (10-20 g) were electrophoresed on a 3-8% Tris-acetate gel (Life Technologies, Carlsbad, CA, USA), transferred to PVDF membrane and subjected to Western blot analysis with specific antibodies. Topo II␣ and topo II␤ antibodies were used at a dilution of 1:2000, myc-tag protein antibody was used at a dilution of 1:2000 and HRP-conjugated antibody to actin was used at a dilution of 1:40000. Anti-rabbit IgG antibody, peroxidase labeled or anti-mouse IgG antibody, peroxidase labeled (SeraCare Life Sciences, Milford, MA, USA) diluted 1:40000 was used as the secondary antibody.
Determination of pseudomitotic index
HTETOP cells expressing WT or mutant forms of topo II␣ or topo II␤ were grown on coverslips in 6 well plates to 60-70% confluence. The cells were then incubated without or with ICRF-193 (2 M) for 2.5 h followed by incubation with 50 ng/ml of colcemid for 0.5 h. Cells were subsequently incubated with 2 ml of a hypotonic solution of 60% sodium citrate (0.8%)/40% potassium chloride (0.075 M) for 20 min at 37
• C and fixed at 4
• C with ice cold methanol/glacial acetic acid (3:1) for an additional 20 min. The cover slips were then mounted onto slides using Vectashield containing DAPI as the mounting media. The number of interphase nuclei as well as normal (absence of (29) . This procedure provides a better estimate of the decatenation checkpoint, compared to the one employing determination of mitotic cells by mitosis-associated phospho-histone H3 staining, since entangled chromosomes would be expected to be observed only for a defective decatenation checkpoint, but not a defective DNA damage checkpoint.
Determination of activation of the DNA damage checkpoint
The activation of the DNA damage checkpoint was determined by examining percent phosphorylation of H2AX using the Muse H2AX activation dual detection kit, essentially as described by the manufacturer. Following treatment of HTETOP transfected cells with DMSO for 3 h, 2 M ICRF-193 for 3 h or 5 M VP-16 for 1 h, 2.5 × 10 6 cells were fixed, permeabilized and incubated with a pair of phospho-specific anti-phospho-histone H2AX (Ser139)-Alexa Fluor 555 conjugated antibody and anti-Histone H2A.X PECy5 conjugated antibody (that detects total levels of Histone H2AX) in multiplex. Use of the two antibodies in multiplex allowed for normalization of the total and phospho levels to accurately estimate the level of H2AX activation. The stained cells were analyzed by the MUSE Cell Analyzer which estimated the percentage of activated (staining positive with the phospho-specific H2AX antibody) and inactivated cells (staining positive only with the anti-Histone H2AX antibody). This information was employed to calculate percent active cells relative to total number of H2AX expressing cells.
Cell sorting and flow cytometry
HTETOP cells ectopically expressing WT topo II␤ and maintained in 1 g/ml Tet had sub-populations of diploid and aneuploid cells (Supplementary Figure S3) . To isolate the diploid population, cells were stained with 4 g/ml Hoechst 33342 for 30-45 min at 37
• C, centrifuged and resuspended at 2 × 10 6 cells/ml in advanced DMEM supplemented with 10% fetal bovine serum and 2 mM Lglutamine. Sorting of the diploid population was carried out in an ICyte Reflection (BD Biosciences, San Jose, CA). The gated region set for the diploid population based on the Hoechst 33342 fluorescence distribution histogram represented 10.1% of the 16.1% gate set. From the 3.9 × 10 6 detected events, 0.31 × 10 6 cells represented the total sorted diploid population. Sorted diploid cells were subsequently cultured in advanced DMEM supplemented with 10% fetal bovine serum and 2 mM L-glutamine in the absence or presence of 1 g/ml Tet. Ploidy and cell cycle phase distribution analysis was carried out in a Beckman Coulter XL (Beckman Coulter, Indianapolis, IN) following staining with propidium iodide.
Decatenation of DNA by purified topo II
In vitro enzymatic activity of recombinant WT or mutant topo II␣ or topo II␤ protein expressed in S. cerevisiae yeast strain, BJ201, (22, 23) was assayed by measuring the decatenation of DNA in a reaction mixture containing 50 mM Tris-HCl, pH 7.9, 88 mM KCl, 10 mM MgCl 2 , 0.5 mM EDTA, 10 mM ATP, 10 mM dithiothreitol, 100 g/ml bovine serum albumin and 150 ng of kDNA. At the end of the desired incubation period the reaction was stopped with 5% SDS and an aliquot of the reaction mixture was subjected to agarose (1%) gel electrophoresis. The gel was stained with ethidium bromide and the amount of decatenated minicircles of kDNA was quantified using an AlphaInnotech Image Analyzer (AlphaInnotech Corp., San Leandro, CA). Specific activity of topo II purified by Ni 2+ -nitrilotriacetic acid-agarose column chromatography (23) was calculated as percent decatenation/pmol of topo II/min. The relative amount of topo II in the purified preparations was determined as previously described (23) .
Determination of anti-tumor drug sensitivity
HTETOP cells expressing WT or mutant topo II␣ or topo II␤, or HL-60/siGFP, HL-60/si-topo II␣, HL-60/si-topo II␤, HL-60/AMSA-R or HL-60/AMSA-R/topo II␤ cells were incubated with varying concentrations of VP-16 or m-AMSA for 1 hour at 37
• C. Following treatment, HTETOP cells were washed and incubated in drug-free medium for 96 hours and viable cell counts determined. For HL-60 cells, following drug treatment cells were washed and plated on soft-agar plates and colonies counted after 7 days (6).
Statistical analysis
Statistical analysis was performed on data sets and significant differences were determined by T-test or Two-way ANOVA followed by Student-Newman-Keuls post-hoc tests when significance was detected.
Crystal structure and CTD sequence analysis
Using the published crystal structure of topo II␣ (30) all atom-to-atom distances within 4.5Å were measured between two regions [(R-1 (593-IVKA. . . GTST-636) that corresponds to a folded 'Greek key'-like motif in topo II␣; R-2 (696-LPEQ. . . YGTA-705) that corresponds to an unstructured loop in topo II␣] with the rest of the amino acids in the topo II␣ dimer. These two regions are missing in the published crystal structures of topo II␤ (31,32), but not in the crystal structure of topo II␣. To do the same measurements for the topo II␤ dimer, the TOPRIM (topoisomerasePrimase) domains of both isoforms were superimposed in PyMol (RMS = 0.5Å) and then to the R-1 and R-2 regions, in topo II␤, were assigned the coordinates of their counterparts from topo II␣, by homology modelling.
The consensus secondary structure prediction for topo II␣ and topo II␤ as previously described (33) and sequence propensities for various PTMs for topo II␣ and topo II␤ CTD were generated. In addition, sequence propensity for intrinsic disorder was scaled to a 0-9 score as described earlier (34) . The similarity score was calculated based on the alignment of the two CTD sequences, using an in-house script with an implemented BLOSUM62 matrix.
RESULTS
Topo II␣ and topo II␤ are required for the decatenation checkpoint
Fidelity of the decatenation checkpoint is essential for maintaining chromosomal integrity and limited information is available on the role of topo II␤ in regulating this critical checkpoint. To test the role of topo II␣ and topo II␤ in regulating the decatenation checkpoint we used three different model systems that differentially express the two isoforms. These included the human HTETOP and HL-60 cell lines and the SV40 transformed MEF cell line described in 'Materials and Methods'. The decatenation checkpoint was assessed by measuring the pseudomitotic index, which corresponds to the ratio of the frequency of pseudomitosis (cells entering mitosis with entangled chromosomes) in cells treated with the topo II catalytic inhibitor, ICRF-193, to the frequency of mitosis in untreated cells (29) . A higher value is indicative of a defective checkpoint, since cells enter mitosis in the presence of entangled chromosomes. As shown in Figure 1A , the pseudomitotic state with entangled chromosomes was observed in ICRF-193 treated topo II␣-or topo II␤-transfected HTETOP cells in which expression of parental Tet-regulated topo II␣ was suppressed by Tet. In these cells normal mitotic chromosomes were rarely observed and if present, the frequency was <0.1% (Supplementary Table S3 ). However, the pseudomitotic index in WT topo II␤-transfected HTETOP cells (+Tet) expressing only WT topo II␤ was lower compared to that in WT topo II␣-transfected HTETOP cells (+Tet) or the parent HTE-TOP cell line (-Tet), predominantly expressing WT topo II␣ and low levels of endogenous topo II␤ ( Figure 1B) . No significant difference in the pseudomitotic index was observed between WT topo II␣-transfected cells and the parent HTE-TOP cell line ( Figure 1B) . In addition to determining activation of the decatenation checkpoint following inhibition of topo II catalytic activity by ICRF-193, we also determined whether this treatment led to activation of the DNA damage checkpoint by measuring phosphorylation of H2AX. Our results revealed that while the DNA-damaging agent VP-16 led to a significant increase in phospho-H2AX positive cells in both WT topo II␣-and WT topo II␤-transfected HTETOP cells, ICRF-193 treatment led to no significant increase in topo II␤-transfected HTETOP cells and a modest increase in topo II␣-transfected cells ( Figure 1C) . These results suggest that like topo II␣, the topo II␤ isoform, is also capable of regulating the decatenation checkpoint and may do so more proficiently than topo II␣. Figure S4) . Following culture of the sorted diploid population as well as the unsorted aneuploid population in the absence or presence of Tet, cells expressing both topo II␣ and topo II␤ or only topo II␤, respectively were tested for their ability to regulate the decatenation checkpoint. The results ( Figure 2C ) revealed that the pseudomitotic index of cells expressing both topo II␣ and topo II␤ (-Tet) was significantly lower (P = 0.002, two-way ANOVA) than that of cells expressing only topo II␤ (+Tet). For the sorted diploid cell population a 3-fold decrease (P = 0.005) in the pseudomitotic index was observed for cells expressing both topo II␣ and topo II␤ (-Tet), compared to those expressing only topo II␤ (+Tet). For the unsorted aneuploid cell population a 1.6-fold decrease (P = 0.055) in the pseudomitotic index was observed for cells expressing both topo II␣ and topo II␤ (-Tet), compared to those expressing only topo II␤ (+Tet). However, no significant difference was observed in the pseudomitotic index of topo II␣-transfected HTETOP cells cultured in the absence or presence of Tet ( Figure 2D ), despite higher level (approximately 2-fold) of expression of topo II␣ in cells cultured in the absence of Tet. Our findings thus indicate that efficient regulation of the decatenation checkpoint requires both topo II isoforms.
Consistent with the observations in HTETOP cells, the decatenation checkpoint in other model systems revealed similar findings. Stable down regulation (8, Supplementary  Figure S2 ) of either topo II␣ (72 ± 7.2%) or topo II␤ (96 ± 4.1%) in HL-60 cells (HL-60/sitopo II␣ or HL-60/sitopo II␤, respectively) led to an increase in the pseudomitotic index compared to control cells (HL-60/siGFP) ( Figure 3A) , confirming that the decatenation checkpoint is regulated by both topo II␣ and topo II␤ and is most efficient when both isoforms are present. Our results demonstrating a higher pseudomitotic index in topo II␤-deficient cells (HL-60/sitopo II␤), which express higher levels of topo II␣ and lower levels of topo II␤ compared to topo II␣-deficient cells, supports our finding in HTETOP cells that the topo II␤ isoform may be more proficient in regulating the decatenation checkpoint. However, it is possible that differential down regulation of topo II␣ (72%) and topo II␤ (96%) in the HL-60/si-topo II␣ and HL-60/si-topo II␤ cell lines, respectively could have contributed to the lower pseudomitotic index observed in HL-60/si-topo II␣ cells. A high pseudomitotic index was also observed in the amsacrine resistant HL-60 cell line (HL-60/AMSA-R), which does not express topo II␤ ( Figure 3B ). Nevertheless, re-expression of topo II␤ in the HL-60/AMSA-R cell line (HL-60/AMSA-R/topo II␤) led to a 4-fold decrease in the pseudomitotic index (Figure 3B) , confirming the role of topo II␤ in the decatenation checkpoint. The pseudomitotic index in topo II␤ −/− mouse embryo fibroblasts (MEF) was also found to be significantly higher than in topo II␤ +/+ fibroblasts ( Figure 3C ). The relatively high pseudomitotic index observed in the topo II␤ +/+ MEF cells, which express both topo II␣ and topo II␤, could be due to transformation of these cells by the SV40 large T antigen, which is known to destabilize the genome.
Deletion of the CTD, while preserving the nuclear localization signal (NLS), differentially modulates the in vitro decatenation activity and decatenation checkpoint whereas mutation of homologous tyrosines, Y640 in topo II␣ and Y656 in topo II␤, attenuates these activities Since the CTDs of topo II␣ and topo II␤ share little homology and are not directly involved in the catalytic activity, it has been suggested that they are involved in regulating the divergent cellular functions of these isoforms. Therefore, we tested C-terminal deletion mutants of topo II␣ and topo II␤ on the in vitro catalytic activity and decatenation checkpoint. For determining this we deleted most of the CTD but retained the region corresponding to the NLS, since the topo II isoforms function in the nucleus. Whereas, deletion of the CTD of topo II␣ led to an approximate 8-fold increase in the decatenation activity compared to WT topo II␣ (Table 1 and Supplementary Figure S5) , deletion of the CTD of topo II␤ resulted in an approximate 10-fold decrease in the decatenation activity compared to WT topo II␤ (Table 1 and Supplementary Figure S6) . Similarly, the pseudomitotic index of HTETOP cells transfected with Cdel topo II␣ was 5-fold lower than that of HTETOP cells transfected with WT topo II␣, even when the WT-topo II␣ transfected cells cultured in the absence of Tet expressed higher levels of topo II␣ ( Figure 4A and Table 2 ). In contrast the pseudomitotic index of HTETOP cells expressing C-del topo II␤ was 1.5-fold higher than HTETOP cells expressing WT topo II␤ ( Figure 4B ).
Previously we reported that mutation of a non-catalytic tyrosine residue, Y656, in topo II␤ decreased its catalytic activity (22, Figure S6) . In this study we show that mutation of a homologous tyrosine, Y640, in topo II␣ also decreased the in vitro decatenation activity of this isoform (Table 1 and Supplementary Figure  S5) . Consistent with this observation the pseudomitotic in- Figure 4A and B). Specifically, a 2.1-fold increase and 3.4-fold increase compared to the WT enzyme was observed for the Y640F topo II␣ and Y656F topo II␤ mutation, respectively. Interestingly, the pseudomitotic index of Y640F mutant topo II␣-and Y656F mutant topo II␤-transfected HTETOP cell lines in the absence of Tet was lower when compared to that in the presence of Tet and was similar to that observed for the parental or WT topo II␣ transfected cells (Table 2) . However, the pseudomitotic index of C-del topo II␣-or C-del topo II␤-transfected cells in the presence of Tet, which was lower than that of WT topo II␣-transfected cells, was unaffected when these cells were cultured in the absence of Tet (Table 2 ). These findings suggest that although the CTDs of topo II␣ and topo II␤ reciprocally modulate the in vitro and in vivo decatenation activity of these isoforms, the homologous non catalytic tyrosine residues (Y640 in topo II␣ and Y656 in topo II␤) similarly influences the in vitro and in vivo decatenation activities of these isoforms. To determine whether ICRF-193 led to DNA damage we examined phosphorylation of H2AX following treatment with ICRF-193 in the WT and mutant topo II␣-and topo II␤-transfected cells. These studies revealed that while ICRF-193 led to a modest phosphorylation of H2AX (approximately 7%) in all transfected cell lines ( Figure 4C and D), no statistically significant differences were observed in H2AX phosphorylation between the different cell lines (two-way ANOVA, Student-Neuman-Keuls post-hoc test). In contrast the DNA damaging agent, VP-16 led to significantly higher phosphorylation of H2AX in all transfected cell lines (P < 0.001, two-way ANOVA, Student-NeumanKeuls post-hoc test) ( Figure 4C and D) . However, no statistically significant differences (two-way ANOVA, StudentNeuman-Keuls post-hoc test) were observed in H2AX phosphorylation between the different cell lines treated with VP-16. 
Deletion of the CTD of topo II␣ or topo II␤ or mutation of Y640 in topo II␣ or Y656 in topo II␤ alters anti-tumor drug sensitivity
Since topo II is an effective clinical target for several chemotherapeutic drugs we wanted to determine the effect of deletion of the CTD or mutation of the homologous non-catalytic tyrosine on drug sensitivity. Therefore, we first tested selectivity of two clinically useful anti-tumor drugs, VP-16 and m-AMSA, for topo II␣ or topo II␤ in HL-60 cells differentially expressing these isoforms. Our results revealed that HL-60/si-topo II␣ cells that are deficient in topo II␣ are significantly more resistant to the cytotoxic effects of VP-16, compared to control HL-60/siGFP cells and HL-60/si-topoII␤ cells that are deficient in topo II␤ ( Figure  5A ). In contrast, HL-60/si-topo II␤ cells that are deficient in topo II␤ are significantly more resistant to m-AMSA compared to the HL-60/siGFP and HL-60/si-topoII␣ cells ( Figure 5B ). Similarly the HL-60/AMSA-R cells are more resistant to m-AMSA compared to the parent HL-60 cell line ( Figure 5C ). However ectopic expression of topo II␤ in the HL-60/AMSA-R cells sensitizes these cells to m-AMSA ( Figure 5C ). These data demonstrate that VP-16 and m-AMSA preferentially target topo II␣ and topo II␤, respectively.
Based on the selectivity of the topo II-targeted drugs, VP-16 and m-AMSA for topo II␣ and topo II␤, respectively we examined the sensitivity of HTETOP cells expressing WT or mutant forms of topo II␣ or topo II␤ to these drugs. Whereas VP-16 cytotoxicity is significantly enhanced in cells expressing C-del topo II␣, VP-16 cytotoxicity is significantly diminished (P < 0.006 at VP-16 >2.5 M) in cells expressing the Y640F mutant enzyme ( Figure 6A ). In contrast cells expressing C-del topo II␤ as well as cells expressing Y656F mutant topo II␤ are significantly more resistant to the cytotoxic effects of m-AMSA compared to cells expressing the WT enzyme ( Figure 6B ). Thus the decatenation checkpoint (Figure 4 ), in vitro catalytic activity (Table 1 and Supplementary Figures S5 and S6 ) and the cytotoxic effects of topo II-targeted drugs ( Figure 6 ) are similarly regulated by the C-terminal region and the homologous non-catalytic tyrosine of topo II␣ and topo II␤.
Structural analysis of topo II␣ and topo II␤
Since the CTD of topo II␣ and topo II␤ is intrinsically disordered and the crystal structure for this region is not available we performed structural alignment of this region to determine whether differences in structural features of topo II␣ and topo II␤ could provide insights into the observed differential effect of the CTDs on topo II activity. As seen in Figure 7A the CTD of topo II␤ is longer with the extra 77 amino acids located in eight major insertions separating predicted secondary structure elements. Starting from amino acid approximately 1385, the last four insertions toward the C-terminus are highly negatively charged and contain multiple phenylalanines. Since acidic amino acids have the lowest DNA interaction propensity (35) and phenylalanine is known to interact more avidly with proteins than DNA this observation suggests the CTD of topo II␤ is prone to protein-protein rather than protein-DNA interactions, at least in the final C-terminal region. Further, prediction of PTMs and recent mass spectrometry based experimental results (36) (37) (38) indicate that the CTD is heavily modified post-translationally by SUMOylation, ubiquitination and phosphorylation, suggesting that this domain is involved in multiple protein-protein interactions. Interestingly, in the case of topo II␤ many of the modified amino acids are found in the insertions: 2 ubiquitination (K1294, K1297) and 5 phosphorylation (T1287, S1395, T1398, T1570, S1571) sites; or right next to the insertions: 1 SUMOylation (K1266), 2 ubiquitination (K1209, K1569) and 4 phosphorylation (S1419, S1436, S1447, S1576) sites. This suggests that topo II␤ CTD might recruit/interact with more proteins to enhance the decatenation activity, which in part might explain the attenuation of topo II␤ activity when the CTD is deleted.
Structural modeling analysis and evaluation of the available crystal structure of the topo II␣ isoform (30) , which preferentially decatenates positive supercoiled DNA (39) in 60
• crossover geometry (40) , revealed that the alignment of topo II␣ CTD restricts passage of the transport (T) DNA through the G gate ( Figure 7B and Supplementary Figure  S7 ). Thus removal of the CTD of topo II␣ would allow the T-segment to pass through the G-gate by simple diffusion, potentially explaining increased topo II␣ activity following C-terminal deletion.
Since both Y640 in topo II␣ and Y656 in topo II␤ are required for the efficient activation of the decatenation checkpoint, we performed structural analysis of the TOPRIM domain surrounding this region. As seen in Figure 7B the DNA crossover geometries in topo II␣ and topo II␤ vary. In the negative supercoiled configuration of the DNA, which is preferred by topo II␤, the T DNA will be on the direction and proximity of Y656 in the TOPRIM domain of topo II␤. In contrast in the positive supercoiled configuration, which is preferred by topo II␣, the T DNA will be in proximity of the CTD. Further, comparison of the recent crystal structures of topo II␣ (pdb: 4FM9) and topo II␤ (pdb: 3QX3, 4G0U, 4G0V, 4G0W, 4J3N) revealed two regions within the TOPRIM domain of topo II␤ that were missing in the electron density of all five topo II␤ structures (31, 32) . These missing regions are: R-1) 593-IVKA. . . GTST-636 -corresponding to a folded 'Greek key'-like motif in topo II␣ and R-2) 696-LPEQ. . . YGTA-705 corresponding to an unstructured loop in topo II␣, close in space to Y640 in topo II␣ (Supplementary Table S4 and Supplementary Figure S8) . The absence of these regions in the electron density of topo II␤ indicates that they can be found in this isoform in multiple configurations. This may be due to some missing critical anchoring contacts with the rest of the protein, anchors that in turn are present in topo II␣, and/or to some configurational shifts induced by a stronger interaction with the T-segment DNA (Supplementary Table S4 ). One indication of missing anchoring contacts is that in the crystal structure of topo II␣ the two regions (R-1 & R-2) are stabilized by a hydrogen bond between topo II␣ E597-Y684. This contact is lost in topo II␤, since Y684 is replaced by F700. Another possible anchor in topo II␣ is the H-bond between S621 at the end of R-1 on one monomer with D963 in the DNA binding domain on the other monomer of the dimer, which is lost in topo II␤ as this serine is replaced with an alanine A637. The loss of favorable contacts is also shown by ho- Columns represent the mean of three biological replicates and the bars indicate standard deviations. **P < 0.01, ***P < 0.001, ****P < 0.0001 (two-sample t-test was used to compare data sets). Columns represent the mean of three biological replicates and the bars indicate standard deviations. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (two-sample t-test was used to compare data sets). mology modeling. Assigning to the R-1 and R-2 regions in topo II␤ the coordinates of their counterparts in topo II␣ by homology modeling, results in a significant loss of favorable contacts between R-1 and R-2 and the rest of the protein (Supplementary Table S4 ). Hence, in topo II␣ there are more interactions contributing to the overall stability of these two regions. Interestingly also, surrounding these 'flexible' R-1 and R-2 regions, the number of basic amino acids in TOPRIM is increased in topo II␤ in comparison to topo II␣, (Supplementary Figure S8) . Including the R-1 and R-2 segments in topo II␤ TOPRIM there are five additional positive charges with respect to topo II␣, while D683 of topo II␣ is replaced by Q699 in topo II␤. All these add up to an increased DNA interaction propensity of topo II␤ TOPRIM in comparison to topo II␣. A possible interpretation of this finding is that the T DNA might interact better and be aligned to TOPRIM in topo II␤, in contrast to what happens in topo II␣.
DISCUSSION
In this study we demonstrate that topo II␣ and topo II␤ isoforms, considered to be functionally distinct, can exhibit redundant activities. The topo II␤ isoform, in the absence of topo II␣, can support cell proliferation (this study, 27, 41) and regulate the decatenation checkpoint. Our findings also indicate that activation of the decatenation checkpoint is more efficient when both topo II␣ and topo II␤ are present. Although the CTD of topo II␣ and topo II␤ as well as the homologous non-catalytic tyrosine residue (Y640 in topo II␣ and Y656 in topo II␤) play a role in regulating the decatenation checkpoint and drug sensitivity, deletion of most of the CTD, while preserving the NLS, reciprocally impacts topo II␣ and topo II␤ function.
Previous reports have implicated a role for topo II␣ in decatenation checkpoint (18) (19) (20) , however most of these studies have not convincingly addressed the role of topo II␤. In several of these studies activation of the checkpoint following treatment with the topo II catalytic inhibitor, ICRF-193, has been attributed to a role of topo II␣ in decatenation checkpoint, despite the ability of ICRF-193 to inhibit both isoforms. However in this study we demonstrate that: (a) the decatenation checkpoint is preferentially regulated in HTETOP cells expressing only topo II␤, compared to those expressing primarily topo II␣ ( Figure 1B) , and (b) topo II␤-deficient HL-60 cells expressing primarily topo II␣ ( Figure 3A ) have a totally inefficient decatenation checkpoint. These findings provide evidence for a role of topo II␤ in the decatenation checkpoint and suggest that topo II␣ alone may not efficiently activate this checkpoint. The ability of topo II␤ to regulate the decatenation checkpoint despite its degradation by ICRF-193 (40-50% after 1 h and 62-68% after 3 h, Supplementary Figure  S9 ), suggests that prior to degradation, the topo II␤ circular clamp structure may be recognized by sensor proteins that initiate activation of the decatenation checkpoint signaling pathway. Alternatively, enough topo II␤ protein may be present following degradation by ICRF-193 to activate the decatenation checkpoint. The preferential role for topo II␤ in regulating the decatenation checkpoint is also consistent with studies demonstrating an inefficient decatenation checkpoint in stem and progenitor cells (29) , which express relatively lower levels of topo II␤ as compared to topo II␣ (42) . In contrast differentiated cells, which have a more proficient decatenation checkpoint, express higher levels of topo II␤ compared to topo II␣ (42) . High expression of topo II␤ in granulosa cells of follicles has also been reported to be essential for regulating genomic integrity and follicle atresia (43) . However, a previous study (19) in hTERT transformed normal human diploid fibroblasts expressing a decatenation defective topo II␤ showed that unlike topo II␣, topo II␤ is inefficient in regulating the decatenation checkpoint. This conclusion was based on their observation that siRNA-targeted depletion of topo II␣, but not topo II␤, attenuated the decatenation checkpoint. Although the reason for this discrepancy is unclear at the present time, it is possible that the decatenation-defective topo II␤ present in their cells is unable to form the closed clamp topo II-DNA structural feature that would be recognized by checkpoint sensor proteins for activating the decatenation checkpoint in topo II␣-deficient cells (17) . Further, topo II␤ expression could also be compromised following degradation by 45) during the 4-6 hr treatment interval used for measuring the mitotic entry rate.
It is not surprising for topo II␣ and topo II␤ to exhibit overlapping functions given the essential nature of the topo II catalytic activity in DNA metabolic processes and cell survival. Thus, the functional activities of the two topo II isoforms could be dynamic and regulated uniquely within cells by distinct mechanisms, including PTMs e.g. phosphorylation and sumoylation, and protein interactions with nuclear protein complexes (21) . These mechanisms could involve specific regions within the topo II protein, potentially the CTD given the divergence (22% identity) within this region between topo II␣ and topo II␤. Indeed our results of C-del topo II␣ and topo II␤, truncated at amino acids 1201 and 1219, respectively, and engineered to retain the NLS sequences (amino acids 1454-1497 for topo II␣ and 1522-1573 for topo II␤) demonstrated that the CTD of topo II␣ and topo II␤ reciprocally regulated the in vitro (decatenation activity) and in vivo (decatenation checkpoint and sensitivity to topo II-targeted drugs) activities of these two isoforms. The C-del topo II␣ isoform was significantly more efficient than full length topo II␣, whereas the C-del topo II␤ isoform was significantly less efficient than full length topo II␤.
The present study directly evaluated the in vivo function of the C-terminal deleted mutants of topo II␣ and topo II␤, whereas other studies have examined the in vitro enzymatic activities of topo II␣ truncated at different amino acids in the C-terminus region. Truncation of topo II␣ at amino acid 1171 was shown to decrease the decatenation activity but enhance the DNA cleavage activity (46) , which was comparable to the results observed for the topo II enzyme from Chlorella virus (47) . In contrast, truncation of topo II␣ at amino acid 1242 did not affect the decatenation activity (48) . These differences may likely be due to deletions of the CTD at different amino acids. It is also possible that our results demonstrating differential regulation of topo II␣ and topo II␤ functional activity by the CTD are due to the presence of the NLS. However, the CTD is less divergent in the NLS (approximate homology 42%) compared to the rest of this region, which suggests that regions other than the NLS may be more important in regulating enzyme function.
Whereas our study examined the in vivo functional role of the CTD of topo II␣ and topo II␤ by expressing a Cterminal deleted enzyme that can be translocated to the nucleus, Linka et al (27) studied the in vivo role of the Cterminus by expressing chimeric topo II enzymes in which the C-terminus of one topo II isoform was exchanged for the C-terminus of the other topo II isoform. Their results revealed an absolute requirement of the C-terminal region of topo II␣ (1173-1531) for in vivo association of topo II with mitotic chromosomes, which contrasts our finding demonstrating that the CTD of topo II␣ spanning amino acids 1201-1454 and 1497-1531 is inhibitory for decatenation. The reason for this discrepancy could be due to truncation of the CTD at different sites, intrinsic functional differences within the C-terminal regions of topo II␣ and topo II␤ or due to a significant structural alteration of topo II␣ or hindrance of its catalytic site by the divergent CTD of topo II␤.
Our previous study demonstrating an important role for tyrosine 656 in topo II␤ for regulating its catalytic activity (22) led us to examine the role of this amino acid and the homologous tyrosine, Y640, in topo II␣ in regulating decatenation checkpoint and drug sensitivity. Mutation of both Y640 in topo II␣ and Y656 in topo II␤ decreased the enzymatic activity, regulation of the decatenation checkpoint, and sensitivity to topo II-targeted drugs. The mechanism by which these tyrosine residues control topo II activity does not involve phosphorylation at this site, since phosphorylation of Y656 was not detected in our previous study (22) and modeling studies did not predict phosphorylation at either Y640 or Y656. These findings suggest that structural features within the CTD, compared to those in the TOPRIM domain, may be more important for modulating the dynamic functional activities of topo II␣ and topo II␤.
Because of the essential role of topo II in several DNA metabolic processes, this enzyme is a key target for clinically effective drugs used for treating several types of cancers. Although it has been assumed that most of these drugs target both isoforms, recent evidence suggests that some of these drugs may target a specific topo II isoform. Indeed in this study we show that VP-16 is more specific for topo II␣, whereas m-AMSA is more specific for topo II␤. The structural features within topo II that determine sensitivity to these drugs are similar to those that influence the decatenation checkpoint. Thus C-terminal deletion of topo II␣ enhances sensitivity to topo II␣-targeted drugs whereas Cterminal deletion of topo II␤ decreases sensitivity to topo II␤-targeted drugs. Mutation of Y640 in topo II␣ and Y656 in topo II␤ both decrease sensitivity of cells to topo II␣-and topo II␤-targeted drugs, respectively. These findings further strengthen the role of these structural features in topo II function.
Since the sequences of the CTD of both topo II␣ and topo II␤ are predicted to be intrinsically disordered, the crystal structure of this domain is not available. However, sequence alignment analysis of the CTDs of topo II␣ and topo II␤ provided potential insights regarding structural differences within this region that might contribute to the opposing regulation of the decatenation checkpoint and drug sensitivity by C-terminal deletion mutants. The presence of additional amino acids in the CTD of topo II␤ that are negatively charged and contain multiple phenylalanines, suggests that at least in topo II␤ the CTD is prone to protein-protein rather than protein-DNA interactions. The large number of predicted PTMs within the CTDs of topo II␤, could also alter protein-protein interactions, such that the proteins recruited by topo II␤ would play an important role in its interaction with and decatenation of its DNA substrate. Thus C-del topo II␤ would not be as proficient in binding and decatenating DNA. In the case of topo II␣, which preferentially relaxes and decatenates positively supercoiled DNA (39) , analysis of the crystal structure suggests that when the CTD is deleted (as shown in the coarse grain model relative to the DNA binding domain in Supplementary Figure S7 ) the DNA T segment freely passes through the G gate by simple diffusion. This structural configuration provides a potential explanation as to why the C-del enzyme is more efficient and functions at a faster rate. However, the report indicating that mutation of the phosphorylation site, serine 1524, in the CTD decreases the ability of the topo II␣ to control the decatenation checkpoint (18) suggests that regulation of topo II␣ enzyme activity by this region may be complex and influenced by collective PTMs at several of the predicted sites.
Comparison of the crystal structure and homology modeling of topo II␣ and topo II␤ within the Y640/Y656 TOPRIM regions of topo II␣ and topo II␤, respectively revealed that the DNA interaction propensity of TOPRIM in topo II␤ is increased compared to topo II␣, since (a) the T DNA in topo II␤ is located on the direction and proximity of Y656, (b) the RI and R2 regions that provide critical anchoring contacts in topo II␣ are lost in topo II␤ and (c) number of basic amino acids in TOPRIM of topo II␤ are increased. These structural features could therefore allow for better interaction and alignment of the TOPRIM domain in topo II␤ with T DNA.
In summary, our study demonstrates that the functional activity of topo II␣ and topo II␤ may not be as exclusive as previously projected and these two isoforms can indeed perform overlapping functions, albeit with different efficiencies. Since topo II activity is required for cell survival, the ability of the constitutive topo II␤ isoform to substitute for the cell cycle regulated topo II␣ isoform would be beneficial, especially under conditions leading to altered expression of topo II␣ during the cell cycle or aberrant regulation of this isoform in proliferating cells. Further, the ability of topo II␣ and topo II␤ to be distinctly regulated would allow one isoform to better compensate for the functional loss of the other. Thus future studies of topo II cellular function or regulation should involve characterization of both isoforms.
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